|
Paxalisib Clinical Trials
5 actively recruiting trials across 2 locations
▲ +1 trial since June 2026
Also known as: GDC-0084, GDC0084, Inhibitor of the phosphatidylinositol 3-kinase (PI3K) /Protein kinase B (AKT)/Mechanistic target of rapamycin (mTOR) pathway, PI3K Inhibitor GDC-0084
Pipeline
Phase 2: 2Phase 1/2: 2Phase 2/3: 1
Top Sponsors
- University of California, San Francisco1
- Sabine Mueller, MD, PhD1
- Institute of Cancer Research, United Kingdom1
- Global Coalition for Adaptive Research1
- Australian & New Zealand Children's Haematology/Oncology Group1
Indications
- Cancer5
- Recurrent Atypical Teratoid/Rhabdoid Tumor1
- Malignant Primary Gliomas1
- Recurrent WHO Grade III Glioma1
- Recurrent Diffuse Midline Glioma, H3 K27M-Mutant1
Other2 trials
Birmingham, Alabama2 trials
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
University of Alabama at Birmingham
Phase 2/3
Combination Therapy for the Treatment of Diffuse Midline Gliomas
University of Alabama at Birmingham
Phase 2
San Francisco, California1 trial
Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)
University of California, San Francisco
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.